Department of Endocrinology, Hospital Universitari de Bellvitge, Barcelona, Spain.
Department of Pathology, Hospital Universitari de Bellvitge, Barcelona, Spain.
Endocrine. 2019 Jan;63(1):36-43. doi: 10.1007/s12020-018-1774-2. Epub 2018 Oct 1.
In 2017, the WHO established that pituicytoma, granular cell tumour (GCT) and spindle cell oncocytoma (SCO) are posterior pituitary tumours (PPT). Recent data suggests that these tumours probably arise from the pituicytes and may constitute a spectrum of a unique histopathological entity. Our aim is to report the clinical findings and surgical outcomes of 16 patients with PPT. We also evaluated the tissue specimens available in light of current knowledge.
Cross-sectional study with retrospective data.
PPT were 7 pituicytomas, 3 GCT and 6 SCO. Patients mean age was 55 years old and 75% were female. Basal hormonal study showed hyperprolactinemia (43.7%) and hypopituitarism (37.5%). There was no case of diabetes insipidus (DI). MRI showed sellar/suprasellar masses with mean size of 19.7mm. PPT was not suspected in any patient. Fifteen patients underwent surgery and complications were common: 20% had perioperative bleeding (one patient died because of a massive haemorrhage), 57.1% hypopituitarism, 35.7% permanent DI and 21.4% underwent a second surgery. Pathological findings shown positivity for thyroid transcription factor 1, vimentin and negativity for cytokeratin and chromogranin A in all specimens evaluated. S100 protein was positive in 88.8% of tumours. Ki67 was ≥ 3% in 66.6% and ranged from 4-7% in SCO.
PPT have similar histology, clinical features and are frequently misdiagnosed as nonfunctioning pituitary tumours. However, post-surgical complications including haemorrhage are common. A high clinical suspicion is needed to presume the diagnosis prior surgery and diminish the high morbidity of these tumours.
2017 年,世界卫生组织(WHO)将垂体细胞瘤、颗粒细胞瘤(GCT)和梭形细胞嗜酸细胞瘤(SCO)确定为垂体后叶肿瘤(PPT)。最近的数据表明,这些肿瘤可能起源于垂体细胞,可能构成一种独特组织病理学实体的谱。我们的目的是报告 16 例 PPT 患者的临床发现和手术结果。我们还根据当前的知识评估了可用的组织标本。
回顾性横断面研究。
PPT 包括 7 例垂体细胞瘤、3 例 GCT 和 6 例 SCO。患者平均年龄为 55 岁,75%为女性。基础激素研究显示催乳素升高(43.7%)和垂体功能减退(37.5%)。无尿崩症(DI)病例。MRI 显示鞍上/鞍旁肿块,平均大小为 19.7mm。没有患者怀疑有 PPT。15 例患者接受了手术,并发症很常见:20%的患者发生围手术期出血(1 例患者因大量出血死亡),57.1%的患者发生垂体功能减退,35.7%的患者发生永久性 DI,21.4%的患者需要再次手术。所有评估的标本均显示甲状腺转录因子 1、波形蛋白阳性,细胞角蛋白和嗜铬粒蛋白 A 阴性。S100 蛋白在 88.8%的肿瘤中呈阳性。Ki67 在 66.6%的肿瘤中≥3%,在 SCO 中范围为 4-7%。
PPT 具有相似的组织学、临床特征,常被误诊为无功能垂体肿瘤。然而,包括出血在内的术后并发症很常见。在手术前需要高度的临床怀疑来推测诊断,以降低这些肿瘤的高发病率。